March 18, 2025 10:22 pm (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
'The controversial ruler died 300 years ago': Uddhav Thackeray questions row over Aurangzeb's tomb | Maha Kumbh showed unity in diversity: PM Modi in Parliament | Think twice before travelling outside US: Indians with H-1B, F-1 visas, green cards warned by immigration attorneys | Mamata Banerjee visits Furfura Sharif, slams Opposition for questioning her intent ahead of 2026 polls | Left, BJP call Mamata's Oxford University invitation fake PhD deja vu, TMC hits back | Violence breaks out in Nagpur over call to remove Aurangzeb's tomb, Fadnavis appeals for peace | Ballet dance between dragon, elephant is the only choice: China after Modi's 'positive' remarks in Lex Fridman podcast | PM Modi meets Tulsi Gabbard, discusses ways to enhance cooperation for tackling terrorism | Trump, Modi are focused on strengthening shared interests of India and US: Tulsi Gabbard | Orry in legal trouble for drinking at Katra hotel near Vaishno Devi pilgrimage site in Jammu and Kashmir
Dr Reddy's labs

Dr Reddy's Labs net profit declines 12.6 pc to Rs 579.3 cr in June qtr

| @indiablooms | Jul 29, 2020, at 08:47 pm

Hyderabad/IBNS: Drug manufacturer Dr Reddy's Labs has said its net profit in the June quarter declined 12.60 per cent to Rs 579.3 crore compared with Rs 662.8 crore during the same quarter last month.

The company said its gross margin rose to 56 per cent from 51.7 per cent while its while its revenue from operations rose 15 per cent annually to Rs 4,417.5 crore.

Earnings before interest, taxes, depreciation, and amortization (EBITDA) or operating profit rose 2 per cent to Rs 1,162 crore.

The Hyderabad based company said revenue from India plummeted 10 per cent annually to Rs 630 crore due to lower prescriptions generated and decline in patients visiting clinics and pharmacies.

"The current quarter's financial performance has been strong across all parameter. l am glad that we have been able to serve our patients well and ensured continuity of business operations despite the challenging times. We have started integration and acquired business from Wockhardt and executed two important licencing arrangements for treatment options for COVID-19. Currently, we are working towards bringing both these drugs to multiple markets," G V Prasad, co-chairman and managing director of Dr Reddy's labs  said in a statement

Its revenue from North America, its biggest market, rose 6 per cent to Rs 1730 crore, mainly due to new products and favourable foreign exchange rate, which was offset by price erosion.

"Our operations have continued without much impact. We continued our engagement with doctors through digital channels, ensured regular supplies of our products to meet with the market demand and continued our R&D activities including few projects pertaining to COVID-19," Dr Reddy's Labs said.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.
Related Videos
FM Nirmala Sitharaman presents Budget 2025 Feb 01, 2025, at 03:45 pm
Nirmala Sitharaman on Budget 2024 Jul 23, 2024, at 09:30 pm
PM Modi on Budget 2024 Jul 23, 2024, at 09:30 pm
Close menu